| | |
| Clinical data | |
|---|---|
| Routes of administration | Oral, intransal, vaporized |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C21H26N4O3 |
| Molar mass | 382.464 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
N-Desethylprotonitazene is a benzimidazole opioid with potent analgesic effects which has been sold as a designer drug. It was first identified in 2024 as an active metabolite of the closely related compound protonitazene, [1] [2] and was found to have less potency than it while still being more potent than fentanyl. [3] [4]
It was discovered in a drug sample from Chicago in June 2025. [3]
{{cite journal}}: CS1 maint: article number as page number (link)